title: Prolegomenon for chronic lymphocytic leukaemia.
abstract: Chronic lymphocytic leukaemia (CLL) is a unique lymphoproliferative disorder that scarcely occurs under the age of 40; thereafter the incidence of CLL increases exponentially with age. CLL is characterized by progressive expansion of malignant CD5+ME+ B-cell clone accompanied by a myriad of cellular and humoral immune defects. Each of them might be linked to different clinically manifested complications such as increasing rate of infections, autoimmune disorders and disturbed immune surveillance against tumour cells. We assume that CLL occurs as a consequence of age-dependent, genetically related functional restrictions of the thymic microenvironment in supporting common lymphoid progenitor cells (CD5+ME+CD4-CD8-) to differentiate into mature T-cell and B-cell descendants. In conjunction with genetic abnormalities developing in B-cell progenitors, presumably expressing P glycoprotein (Pgp+), we postulate that developmentally altered T-cell descendants, along with quantitative imbalance among CD4+, their subsets and CD8+ lymphocytes in the peripheral blood, play an important additional role in facilitating the malignant B-cell clone emergence and in modulating the CLL clinical evolution. Namely, imbalance of any of T-cell-mediated cell interactive homeostatic mechanisms accompanied by imbalance in the production of various cytokines might in CLL influence leukaemic B-cell growth by deregulating inducer (c-myc and p53) and/or suppressor (bcl-2 and mutant p53) oncogenes responsible for the promotion or suppression of B-cell mitogenesis that may in turn further contribute to their impaired differentiation and/or differentiation arrest. In conclusion, CLL might be interpreted as a primary immunodeficiency syndrome developing in elderly population due to gradually evolving restriction of genetically controlled programs in the thymic microenvironment responsible for irregular maturation of common lymphoid progenitor cells that constitutively express CD5 antigen and ME receptor into T-cell and B-cell descendants.
authors.affiliation: Department of Molecular Medicine, Merkur University Hospital, Zagreb, Croatia. vitale@rudjer.irb.hr
authors.forename: B
authors.initials: B
authors.lastname: Vitale
authors.forename: M
authors.initials: M
authors.lastname: Martinis
authors.forename: M
authors.initials: M
authors.lastname: Antica
authors.forename: B
authors.initials: B
authors.lastname: Kusić
authors.forename: S
authors.initials: S
authors.lastname: Rabatić
authors.forename: A
authors.initials: A
authors.lastname: Gagro
authors.forename: R
authors.initials: R
authors.lastname: Kusec
authors.forename: B
authors.initials: B
authors.lastname: Jaksić
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D002450:Cell Communication; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000209:etiology* / Q000235:genetics / Q000276:immunology; D011110:Polymorphism, Genetic; D011379:Prognosis; D013601:T-Lymphocytes / Q000276:immunology; D013950:Thymus Gland / Q000502:physiology